Moreover, this approach comes with added advantages such as (1) PP2A activators are orally bioavailable and well tolerated across preclinical models of pediatric cancer, including NB [9,30]; (2) PP2A reactivation targets MYCN at the protein level, resulting in its degradation; and (3) the specificity of these small molecules to PP2A has been validated across pediatric cancers, again including NB [9,30]. This evidence concerns the gene MYCN and neuroblastoma.